514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus Bacteremia
Conditions
Staphylococcus Aureus Bacteremia
Trial Timeline
May 1, 2015 → Dec 1, 2016
NCT ID
NCT02357966About 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II is a phase 1/2 stage product being developed by XBiotech for Staphylococcus Aureus Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT02357966. Target conditions include Staphylococcus Aureus Bacteremia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02357966 | Phase 1/2 | Completed |
Competing Products
12 competing products in Staphylococcus Aureus Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 77 |
| AZD7760 | AstraZeneca | Phase 1/2 | 41 |
| V710 + Placebo | Merck | Phase 2/3 | 65 |
| Daptomycin | Merck | Phase 2 | 52 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 52 |
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 51 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 22 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |